top of page
Entresto Logo 2020.png

HFSN competency workshop

This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Limited.

UK | March 2022 | 193547

Entresto (sacubitril/valsartan) is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.


Adverse events should be reported. Reporting forms and information can be found at (UK).

Adverse events should also be reported to Novartis via or online through the pharmacovigilance intake (PVI) tool at


If you have a question about a product, please contact Medical Information on 01276 698370 or by email at

To learn about your data privacy rights and the use of your personal information, we invite you to read our General Privacy Notice for Business Partners.

bottom of page